AbbVie Already Has The Next Humira

Summary:

  • AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively.
  • I expect Skyrizi to become a bigger product for AbbVie than Humira was at its peak in 2021.
  • Skyrizi’s robust efficacy and good safety in psoriasis, psoriatic arthritis, and inflammatory bowel diseases support its strong long-term growth prospects.
  • AbbVie’s strategic acquisitions and pipeline assets, including TL1A antibody FG-M701, are set to enhance Skyrizi’s market potential and overall company growth.

next big thing ahead

honglouwawa/iStock via Getty Images

AbbVie (NYSE:ABBV) is up slightly more than 20% since my late April article, in which I initiated bullish coverage based on better-than-expected performance of several key products and recent acquisition announcements that have


Analyst’s Disclosure: I/we have a beneficial long position in the shares of ROIV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


I publish my best ideas and top coverage on the Growth Stock Forum. If you’re interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

Leave a Reply

Your email address will not be published. Required fields are marked *